[CAS NO. 1983984-01-5] Avotaciclib trihydrochloride
PRODUCTS SPECIFICATIONS [1983984-01-5]
DESCRIPTION [1983984-01-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 390.66 |
| Molecular Formula | C13H14Cl3N7O |
| SMILES | OC1=CC=C(C2=NC(N)=NC=C2)N=C1C3=NC(N)=NC=C3.[H]Cl.[H]Cl.[H]Cl |
Summary
Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1) . Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer [1] .
IC50 & Target
|
CDK1 |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05093907 | BeyondBio Inc. |
Metastatic Colorectal Cancer
|
August 31, 2021 | Phase 1|Phase 2 |
| NCT03579836 | BeyondBio Inc. |
Locally Advanced or Metastatic Pancreatic Cancer
|
May 1, 2018 | Phase 1|Phase 2 |
| NCT05769660 | BeyondBio Inc. |
Glioblastoma Multiforme
|
November 29, 2022 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 5 mg/mL ( 12.80 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.5598 mL | 12.7989 mL | 25.5977 mL |
| 5 mM | 0.5120 mL | 2.5598 mL | 5.1195 mL |
| 10 mM | 0.2560 mL | 1.2799 mL | 2.5598 mL |